Expanded Partnership with Medidata Supports Karyopharm’s Mission to Develop First-in-Class Therapeutics

Adoption of additional technology solutions demonstrates commitment to patients with cancer and other serious diseases

New York, New York – March 10,  2021 – Medidata, a Dassault Systèmes company and the global leader in creating end-to-end solutions to support the entire clinical development process, today announced its expanded partnership with Karyopharm Therapeutics (NASDAQ: KPTI). In 2014, Karyopharm selected one Medidata technology solution for a single study. Today, the company is leveraging 10 solutions in Medidata Rave Clinical Cloud in more than 15 clinical studies focused on hematologic malignancies and solid tumors.

“Medidata is pleased to play a key role in supporting Karyopharm’s mission of bringing novel therapies to market, providing hope for patients,” said Glen de Vries, co-founder and co-CEO, Medidata. ”This agreement is a clear demonstration of our shared mission to advance analytics and technology to make a difference in health care.”

With Medidata solutions, Karyopharm is able to:

  • Centralize operations, eliminate manual data entry, and operate with a clear view of all cross-application data in one place
  • Simplify and customize reporting within or across studies and leverage over 30 standard reports
  • Reduce complexity by standardizing and improving data quality with powerful artificial intelligence and machine learning algorithms that automatically manage the complexity of clinical data

“Medidata continues to be an important strategic partner for Karyopharm by providing a cutting-edge technological infrastructure that helps us reach our clinical trial goals,” said Kristan Gallitano, senior vice president, Development Operations at Karyopharm. “Medidata provides us the flexible, scalable technology and support we need to meet the evolving challenges of drug development.”
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit https://www.3ds.com